Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus dacarbazine for progressive metastatic pancreatic neuroendocrine tumors
2024-515045-42-00Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in islet cell tumor, sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Disease control rate at 6 months. Started Oct 2024; status: completed.
02
Drugs
ramucirumab
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2024-515045-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515045-42-00.